Double maintains 2 strategies that include ABUS - Arbutus Biopharma Corp.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -29.43% | $164.54M | 0.85% |
| TAIL | -29.14% | $99.63M | 0.59% |
| BTAL | -16.00% | $296.22M | 1.43% |
| FTSD | -12.05% | $231.81M | 0.25% |
| UGA | -11.24% | $72.33M | 0.97% |
| IVOL | -10.15% | $347.03M | 1.02% |
| KCCA | -10.09% | $109.43M | 0.87% |
| TPMN | -9.75% | $30.70M | 0.65% |
| ULST | -9.02% | $654.75M | 0.2% |
| DBE | -8.93% | $52.20M | 0.77% |
| WEAT | -8.39% | $117.15M | 0.28% |
| USL | -8.34% | $42.23M | 0.85% |
| BNO | -8.22% | $103.79M | 1% |
| USO | -7.69% | $1.13B | 0.6% |
| OILK | -7.63% | $71.87M | 0.69% |
| GBIL | -5.02% | $6.37B | 0.12% |
| TFLO | -4.69% | $6.82B | 0.15% |
| PDBC | -4.63% | $4.42B | 0.59% |
| DBC | -4.63% | $1.23B | 0.87% |
| COMT | -4.56% | $604.69M | 0.48% |
Current Value
$3.201 Year Return
Current Value
$3.201 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IDYA | 46.23% | $1.85B | -37.37% | 0.00% |
| DNLI | 44.57% | $2.03B | -35.83% | 0.00% |
| IMVT | 44.28% | $2.76B | -39.10% | 0.00% |
| UNIT | 42.09% | $1.08B | +59.42% | 0.00% |
| IQV | 41.76% | $28.13B | -21.62% | 0.00% |
| KRYS | 40.80% | $4.02B | -21.73% | 0.00% |
| MSA | 40.16% | $6.73B | -7.25% | 1.21% |
| SYRE | 40.08% | $934.88M | -34.89% | 0.00% |
| ESS | 39.72% | $18.33B | +4.32% | 3.53% |
| BMRN | 39.66% | $10.78B | -31.66% | 0.00% |
| BDTX | 39.21% | $141.02M | -41.09% | 0.00% |
| FRT | 39.17% | $8.13B | -6.83% | 4.67% |
| ATXS | 39.12% | $306.44M | -39.46% | 0.00% |
| ROIV | 38.93% | $7.44B | +3.60% | 0.00% |
| MGTX | 38.92% | $520.77M | +64.47% | 0.00% |
| TECH | 38.77% | $8.16B | -26.90% | 0.62% |
| AMGN | 38.64% | $156.21B | -6.52% | 3.18% |
| KW | 38.63% | $970.82M | -29.59% | 6.78% |
| DAWN | 38.39% | $670.00M | -50.89% | 0.00% |
| IONS | 38.28% | $6.36B | -11.52% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| UDN | 0.37% | $148.33M | 0.78% |
| TBLL | 0.42% | $2.13B | 0.08% |
| AGZD | -0.52% | $102.70M | 0.23% |
| UNG | -0.65% | $360.54M | 1.06% |
| UUP | 0.78% | $201.63M | 0.77% |
| CORN | -1.15% | $44.67M | 0.2% |
| USDU | -1.38% | $162.43M | 0.5% |
| SHV | -1.49% | $20.64B | 0.15% |
| CLIP | -1.59% | $1.51B | 0.07% |
| LDUR | 1.65% | $929.65M | 0.5% |
| FTGC | 2.02% | $2.39B | 0.98% |
| PSQA | 2.13% | $35.44M | 0.2% |
| USCI | 2.15% | $241.75M | 1.07% |
| STPZ | 2.22% | $450.47M | 0.2% |
| XONE | -2.40% | $625.28M | 0.03% |
| SOYB | 2.83% | $26.67M | 0.22% |
| FXE | -2.92% | $568.94M | 0.4% |
| ASHR | 3.05% | $1.91B | 0.65% |
| CANE | -3.29% | $10.37M | 0.29% |
| SPTS | 3.38% | $5.80B | 0.03% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 52.12% | $4.82B | 0.35% |
| IBB | 51.96% | $5.26B | 0.45% |
| BBH | 49.66% | $330.62M | 0.35% |
| FBT | 47.21% | $1.01B | 0.54% |
| PBE | 46.63% | $223.19M | 0.58% |
| XPH | 46.25% | $147.96M | 0.35% |
| KBWY | 44.83% | $225.77M | 0.35% |
| GNOM | 44.57% | $44.57M | 0.5% |
| PINK | 43.90% | $130.57M | 0.5% |
| FHLC | 43.50% | $2.44B | 0.084% |
| VHT | 43.28% | $15.35B | 0.09% |
| FXH | 42.84% | $903.07M | 0.62% |
| BBHY | 42.68% | $604.50M | 0.07% |
| IHE | 42.16% | $550.45M | 0.39% |
| DFGR | 42.13% | $2.53B | 0.22% |
| USHY | 42.09% | $23.83B | 0.08% |
| SRET | 41.96% | $186.24M | 0.59% |
| SCYB | 41.95% | $1.16B | 0.03% |
| IYH | 41.91% | $2.73B | 0.39% |
| RSPH | 41.81% | $729.81M | 0.4% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DRD | -<0.01% | $1.15B | +55.76% | 2.05% |
| CNK | 0.03% | $3.46B | +40.52% | 0.53% |
| AIFU | 0.06% | $6.51B | +93.75% | 0.00% |
| CYD | -0.17% | $876.80M | +155.41% | 3.92% |
| AQB | -0.34% | $2.87M | -53.40% | 0.00% |
| NEUE | 0.66% | $61.16M | +29.25% | 0.00% |
| RLX | 0.74% | $2.05B | +23.63% | 0.43% |
| BTU | 0.78% | $1.60B | -43.87% | 2.15% |
| FARO | 0.78% | $848.40M | +175.36% | 0.00% |
| CNX | 0.78% | $4.66B | +30.77% | 0.00% |
| TK | -0.80% | $608.32M | +7.49% | 0.00% |
| AMR | 0.83% | $1.37B | -67.82% | 0.00% |
| KR | 0.89% | $47.17B | +41.48% | 1.81% |
| CREG | -0.96% | $5.66M | -79.19% | 0.00% |
| VSA | 1.02% | $8.76M | -18.25% | 0.00% |
| ZCMD | -1.12% | $29.29M | -6.45% | 0.00% |
| CALM | 1.16% | $5.43B | +64.80% | 6.59% |
| CNR | -1.21% | $3.44B | -36.77% | 1.02% |
| VRCA | 1.38% | $55.59M | -91.95% | 0.00% |
| CPSH | 1.45% | $39.66M | +61.54% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DFDV | -15.45% | $309.70M | +2,106.40% | 0.00% |
| HUSA | -8.84% | $21.26M | -8.69% | 0.00% |
| MCK | -8.21% | $90.90B | +24.44% | 0.39% |
| OCFT | -7.31% | $264.91M | +355.70% | 0.00% |
| SYPR | -5.27% | $46.42M | +9.19% | 0.00% |
| K | -5.00% | $27.71B | +40.85% | 2.85% |
| LITB | -4.64% | $22.07M | -77.41% | 0.00% |
| FUBO | -4.25% | $1.29B | +187.79% | 0.00% |
| CLLS | -3.97% | $111.75M | -18.42% | 0.00% |
| UUU | -3.54% | $6.98M | +97.39% | 0.00% |
| CCEC | -3.20% | $1.02B | +3.91% | 2.54% |
| VHC | -3.08% | $48.79M | +87.46% | 0.00% |
| MVO | -2.69% | $66.70M | -38.30% | 21.83% |
| MKTX | -1.88% | $8.37B | +15.12% | 1.35% |
| LPTH | -1.82% | $129.55M | +117.27% | 0.00% |
| GORV | -1.64% | $27.11M | -91.06% | 0.00% |
| GFI | -1.59% | $21.24B | +58.84% | 2.32% |
| PSQH | -1.57% | $97.45M | -38.51% | 0.00% |
| BTCT | -1.55% | $22.63M | +43.33% | 0.00% |
| SRRK | -1.53% | $3.21B | +342.46% | 0.00% |
Yahoo
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that it has reacquired China rights to its lead compound, imdus
Finnhub
Arbutus Biopharma Corporation and Qilu Pharmaceutical Co. Ltd. announced that certain Technology Transfer and Exclusive License Agreement, by and among Arbutus and Qilu Pharmaceutical Co. Ltd. has...
SeekingAlpha
Tourlite Fund, LP returned â4.6% for the First Quarter of 2025. Click here to read the full fund letter.
SeekingAlpha
abrdn Life Sciences Investors Q1 2025 Commentary
Yahoo
Arbutus (ABUS) delivered earnings and revenue surprises of -44.44% and 10.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
WARMINSTER, Pa. AP) — Arbutus Biopharma Corp. ABUS) on Wednesday reported a loss of $24.5 million in its first quarter.
